CuraGen News

Connecticut Innovations has appointed a fourth managing director to its deal team, the venture investing arm of the Connecticut state government announced today.

A second former CuraGen Corp. executive has gone to the venture capital side. Canaan Partners announced this morning that former CuraGen CEO Tim Shannon, M.D., has joined the firm's Westport, Conn.

Canaan Partners, a multibillion-dollar global venture capital firm, announced today the appointment of Tim Shannon, M.D., to venture partner.

Connecticut Innovations, the quasi-public state agency that invests in young local technology companies, on Monday appointed a former CuraGen Corp.

The Branford biotech firm CuraGen Corp., which recently completed its sale to Celldex Therapeutics for $93.5 million, will continue to operate in Connecticut as a tiny unit of its new owner.

Companies mentioned in this article: Celldex Therapeutics, Inc. NEEDHAM, Mass. & BRANFORD, Conn.

Neurogen Corp. and Curagen Corp., homegrown drug development firms, now have one more thing in common - both are selling themselves to companies that will shutter all, or virtually all, Connecticut operations.

Last month at the ASCO meeting, Curagen presented results for its lead drug, CR-011, in breast cancer and melanoma patients.

CuraGen Corporation announced today that its Phase I/II Trial evaluating CR011-vcMMAE for the treatment of patients with advanced breast cancer has met the efficacy criteria for advancement to the second stage of enrollment.

TAMPA, Fla.-- --Peter W. Zinober, a shareholder with international law firm Greenberg Traurig P.A., was named one of the nation's "Top 100 Employment Attorneys for 2009" by Human - BENSALEM, Pa.-- --Law Offices of Howard G. Smith announces that it is investigating potential claims against the board of directors of CuraGen Corporation --Itron Inc.

COLUMBUS, Ohio-- --Kentrox , Inc., an innovator of site monitoring, management, and control solutions for service providers, announces immediate availability of Optima Management Portal 7.0 for - NEW YORK-- --Broadpoint Securities Group, Inc.

PRNewswire-FirstCall/ -- CuraGen Corporation reported three data presentations from its ongoing clinical trials of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, in patients with advanced breast cancer and melanoma at the 2009 Annual Meeting of the American Society of Clinical Oncology in Orlando, Florida.

Miramar, FLA. -- Wall Street News Alert is issuing its "Daily Market Movers Report" for Friday morning.

News of Celldex Therapeutics Inc. acquiring CuraGen Corp. for $94.5 million not only highlights a dealmaking trend we're tracking but signifies the need for a broader consolidation that could literally save lives.

CuraGen Corp., a pioneer of Connecticut's biotech industry, has agreed to sell itself to a Massachusetts biotech firm for $95 million, the companies said today.

Celldex Therapeutics Inc. took another step toward expanding its pipeline, agreeing to buy CuraGen Corp.

Ethan Deford, a bioprocess engineer at CuraGen Corp., separates protiens created in cells cultivated by the company in this 2006 file photo.

Conference call scheduled for Friday, May 29, 2009 at 8:30 AM ET-- Transaction adds 11 oncology-focused antibodies, including CR011, to expand Celldex's Precision Targeted Immunotherapy Platform Increases potential value of both CuraGen and Celldex assets through combined technologies and intellectual property Increases Celldex's pro forma cash to ...

The titles, dates, and times of the presentations are as follows: #9032 A phase I/II study of CR011-vcMMAE, an antibody-drug conjugate targeting glycoprotein NMB in patients with advanced melanoma.

CuraGen Corporation has filed its 10Q for the period ended March 31, 2009 . CRGN's stock has risen strongly over the last few months, and is now trading at $1.02, giving it a market capitalization slightly higher than our estimate of its liquidation value.